Relmada Therapeutics (RLMD) Revenue (2012 - 2013)
Relmada Therapeutics (RLMD) posted quarterly Revenue of $1850.0 for Q4 2013, down 13.91% year-over-year from $2149.0 in Q4 2012, and up 191.8% quarter-over-quarter from $634.0 in Q2 2013.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Revenue (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Revenue for 2 consecutive years, with $1850.0 the latest figure, recorded in Q4 2013.
- In Q4 2013, Revenue fell 13.91% year-over-year to $1850.0; the TTM figure through Nov 2013 stood at $4830.0 (changed N/A YoY), while the FY2013 annual figure was $5129.0, down 35.41% from the prior year.
- Revenue advanced to $1850.0 in Q4 2013 per RLMD's latest filing, from $634.0 in the prior quarter.
- Across five years, Revenue topped out at $2346.0 in Q1 2013 and bottomed at $400.0 in Q2 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Relmada Therapeutics | 492.21 Mn | 492.21 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Nov 30, 2013 | 1,850.00 |
| May 31, 2013 | 634.00 |
| Feb 28, 2013 | 2,346.00 |
| Nov 30, 2012 | 2,149.00 |
| Aug 31, 2012 | 1,515.00 |
| May 31, 2012 | 400.00 |